ライフサイエンスコーパス: methylprednisolone

1 he number of emergency visits and dosages of methylprednisolone.

2 buted to epidural injections of contaminated methylprednisolone.

3 unosuppressed after MI with cyclosporine and methylprednisolone.

4 rade, level of injury, and administration of methylprednisolone.

5 or 3 days or placebo as an add-on therapy to methylprednisolone.

6 anti-CD52 monoclonal antibody alemtuzumab or methylprednisolone.

7 those resulting from treatment with topical methylprednisolone.

8 oval of doxycycline and were unresponsive to methylprednisolone.

9 blinding, and directly compared Hyalgan with methylprednisolone.

10 hromatography for levels of prednisolone and methylprednisolone.

11 renal failure when compared with intravenous methylprednisolone.

12 Acute rejection and SCAR were treated by methylprednisolone.

13 hemotherapy, and 2 improved with intravenous methylprednisolone.

14 bclinical rejections were treated with bolus methylprednisolone.

15 te outbreak due to injection of contaminated methylprednisolone.

16 5-2005, Leiden cohort, n = 153) treated with methylprednisolone.

17 ne or in combination with the corticosteroid methylprednisolone.

18 in inhibitor, short-course methotrexate, and methylprednisolone.

19 andomly assigned: 30 to gentamicin and 30 to methylprednisolone.

20 ng pain following injections of contaminated methylprednisolone.

21 ns associated with injection of contaminated methylprednisolone.

22 on 20 March 2020 using early, short-course, methylprednisolone 0.5 to 1 mg/kg/day divided in 2 intra

23 5% and 16 patients were treated with topical methylprednisolone 0.5% twice daily for 10 weeks, in add

24 High concentrations of methylprednisolone (0.32 mg/mL) accelerated growth and a

25 /6 mice, without or with topical therapy, 1% methylprednisolone, 0.025% doxycycline, or physiologic s

26 opical formulations containing 5% IL-1Ra, 1% methylprednisolone, 0.05% cyclosporin A, and a vehicle c

27 f the patients were treated with intravenous methylprednisolone 1 g daily for 3 days and then tapered

28 aper therapy (PCT) consisting of intravenous methylprednisolone 1 gm daily for 1 week followed by ora

29 We suggest the use of IV methylprednisolone 1 mg/kg/day in patients with early mo

30 e prospectively randomized to receive either methylprednisolone 1,000 mg followed by a 3-month steroi

31 After treatment with high-dose methylprednisolone (1 g/day, intravenously, for 3-5 days

32 lind, placebo-controlled study to receive IV methylprednisolone (15 mg/kg of ideal body weight/day) o

33 lly numbered envelopes to receive placebo or methylprednisolone 16 mg/kg/day (</=1000 mg) for 3 days.

34 Patients were randomized to receive methylprednisolone 2 mg/kg per day plus etanercept, myco

35 ght atriotomy with antiinflammatory therapy (methylprednisolone 2 mg/kg per day) (antiinflammatory gr

36 ion at the site of injection of contaminated methylprednisolone, 21% had an abnormal MRI, and all but

37 of cardiopulmonary bypass to receive either methylprednisolone (250 mg at anaesthetic induction and

38 /kg), antithymocyte globulin (90 mg/kg), and methylprednisolone (3 mg/kg).

39 mbination including IVIG 1 g/kg, intravenous methylprednisolone 30 mg/kg, Vinca alkaloids (VCR 0.03 m

40 double-blind randomized controlled trial of methylprednisolone (30 mg/kg) or placebo after the induc

41 ere randomly assigned to receive intravenous methylprednisolone, 30 mg per kilogram of body weight (1

42 reduction; P = 0.02), but was marginal with methylprednisolone (32% reduction; P = 0.06).

43 pants were randomized to receive intravenous methylprednisolone (4 mg/kg/d for 2 weeks) and oral pred

44 mization, patients in the VSE group received methylprednisolone (40 mg) and patients in the control g

45 groups (37 patients each) received 80 mg of methylprednisolone, 40 mg of methylprednisolone, or plac

46 surgery were 73%, 81%, and 92% in the 80-mg methylprednisolone, 40-mg methylprednisolone, and placeb

47 Corticosteroid therapy consisted of either methylprednisolone, 500 mg intravenously for 3 days, or

48 (1:1) by a block design to two intratympanic methylprednisolone (62.5 mg/mL) or gentamicin (40 mg/mL)

49 In addition, methylprednisolone (a synthetic glucocorticoid) treatmen

50 A 3-day course of methylprednisolone accompanied gene transfer without fur

51 ecrosis of the femoral head induced by depot methylprednisolone acetate (depomedrol).

52 third-stage larvae and treated for 6 wk with methylprednisolone acetate (MPA), a synthetic glucocorti

53 fections linked to injection of contaminated methylprednisolone acetate (MPA).

54 gitis among patients exposed to contaminated methylprednisolone acetate (MPA).

55 meningitis due to injections of contaminated methylprednisolone acetate can present with vascular seq

56 0 units daily for 3 days and 1gr intravenous methylprednisolone acetate for 3 days followed by 1 mg/k

57 fungal outbreak associated with contaminated methylprednisolone acetate injections.

58 ucocorticoid injections of preservative-free methylprednisolone acetate prepared by a single compound

59 ssociated with the injection of contaminated methylprednisolone acetate produced by the New England C

60 ingitis linked to contaminated injections of methylprednisolone acetate produced by the New England C

61 However, coadministration of methylprednisolone acetate results in robust hyphal tiss

62 ociated with injections of preservative-free methylprednisolone acetate that was purchased from a sin

63 ll persons potentially exposed to implicated methylprednisolone acetate was conducted by federal, sta

64 Three lots of methylprednisolone acetate were recalled by the pharmacy

65 Contamination of methylprednisolone acetate with the black mold, Exserohi

66 d rabbits (treated with weekly injections of methylprednisolone acetate).

67 of fungal meningitis related to contaminated methylprednisolone acetate.

68 r joint injections with contaminated lots of methylprednisolone acetate.

69 of 1 injection (range, 1 to 6) of implicated methylprednisolone acetate.

70 50 mg of cyclophosphamide, and 100-250 mg of methylprednisolone, administered on 2 occasions 2 weeks

71 Prolonged methylprednisolone administration accelerated the resolu

72 cocorticoid resistance and whether prolonged methylprednisolone administration accelerates the suppre

73 into a randomized trial evaluating prolonged methylprednisolone administration in unresolving ARDS ha

74 There were no SAEs clearly related to methylprednisolone administration, and methylprednisolon

75 ntinued to show superior efficacy over pulse methylprednisolone alone for treatment of lupus nephriti

76 with simvastatin alone or with high dose of methylprednisolone alone or in combination with simvasta

77 4 T cells, CD8 T cells, and NK cells or with methylprednisolone alone.

78 re tested: (1) low-dose cyclophosphamide and methylprednisolone and (2) fludarabine.

79 as greater in patients who received 80 mg of methylprednisolone and 40 mg of methylprednisolone than

80 Of these, 65 were treated with anakinra and methylprednisolone and 55 were untreated historical cont

81 Rats treated concomitantly with methylprednisolone and a broad-spectrum matrix metallopr

82 0-increased MMP-9 secretion was inhibited by methylprednisolone and also by compound A, a novel nonst

83 BALB/c mice underwent immunosuppression with methylprednisolone and antibodies specific for CD4 T cel

84 After immunosuppression with methylprednisolone and antibodies, EA and beta-gal were

85 The choice between methylprednisolone and gentamicin should be made based o

86 7-5.24), and treatment with a combination of methylprednisolone and intravenous immunoglobulin (OR 2.

87 The most common safety outcomes in the methylprednisolone and placebo group were infection (465

88 Treatment with methylprednisolone and several broad-spectrum MMPIs, inc

89 steroids (betamethasone, triamcinolone, and methylprednisolone) and three local anesthetics (lidocai

90 nary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor a

91 Her symptoms stabilized with intravenous methylprednisolone, and her cancer was treated with carb

92 d 92% in the 80-mg methylprednisolone, 40-mg methylprednisolone, and placebo groups, respectively.

93 improvement several days later, tocilizumab, methylprednisolone, and therapeutic anticoagulation were

94 l, other particulate steroids (prednisolone, methylprednisolone, and triamcinolone) caused often imme

95 d only after treatment with 5% IL-1Ra and 1% methylprednisolone, and were absent after cyclosporin A

96 Although methylprednisolone appears to be safe, it did not provid

97 d dexamethasone, spironolactone, and 6-alpha-methylprednisolone as major contributors to corticostero

98 All patients were treated with methylprednisolone at 2 mg/kg/day, but failed to respond

99 Methylprednisolone at a dose of 2 mg/kg or daily equival

100 Intravenous methylprednisolone at a standard anti-inflammatory dose

101 the study; IOP increased significantly with methylprednisolone at week 10 (P = 0.04).

102 tient characteristics that make prophylactic methylprednisolone beneficial.

103 HR consisted of a methylprednisolone bolus and infusions of vasopressin an

104 Hormonal resuscitation consisted of a methylprednisolone bolus and infusions of vasopressin an

105 on days 0 and 4 postoperatively, preceded by methylprednisolone boluses.

106 Glucocorticoids, including dexamethasone, methylprednisolone, budesonide, and fluticasone, potenti

107 after Exserohilum rostratum contamination of methylprednisolone by the New England Compounding Center

108 er one cycle of chemotherapy with etoposide, methylprednisolone, cisplatin, and cytarabine in patient

109 At 3 mo, 33 (49%) of 67 after intravenous methylprednisolone compared with 48 (69%) or 70 after pl

110 tial inflammatory response, the acute use of methylprednisolone compared with placebo decreased treat

111 Methylprednisolone, compared with placebo, did not reduc

112 s were compared at PIIRS diagnosis and after methylprednisolone completion.

113 spinal cord injury is controversial; however methylprednisolone continues to be widely employed in th

114 lprednisolone or conventional nutrition plus methylprednisolone (controls).

115 Exposure to methylprednisolone could enhance the virulence of E. ros

116 Rats treated with 2 mg/kg of methylprednisolone daily for 1, 2, or 4 weeks had an inc

117 On days 3 and 7, methylprednisolone decreased interleukin-6 and increased

118 Methylprednisolone decreased interleukin-6 by days 3 and

119 The glucocorticoids methylprednisolone, deflazacort, and prednisone increase

120 Methylprednisolone did not have a significant effect on

121 As compared with placebo, methylprednisolone did not increase the rate of infectio

122 te rejection or antirejection treatment with methylprednisolone did not increase the risk of BKV repl

123 ed to methylprednisolone administration, and methylprednisolone did not increase viral load.

124 cretion of nasal polyp patients treated with methylprednisolone, doxycycline, anti-IL-5, or placebo.

125 N), number of emergency visits and dosage of methylprednisolone during a 16-week period were compared

126 jections with a cumulative dose of 3.24 g of methylprednisolone during a 9-week period with good tole

127 allograft had a lower risk of resistance to methylprednisolone during AR (odds ratio, 0.29; 95% conf

128 essors, combined vasopressin-epinephrine and methylprednisolone during CPR and stress-dose hydrocorti

129 nistration of a 3-day regimen of intravenous methylprednisolone either in an outpatient clinic (n=69)

130 L exposed to plasma samples collected during methylprednisolone exhibited significant progressive inc

131 Intraoperative methylprednisolone failed to show an overall significant

132 Both groups received 3 days of pulse methylprednisolone followed by a tapering course of oral

133 Treatment with methylprednisolone for 1 wk (n = 8) at 4 wk after immuni

134 ents were initially commenced on intravenous methylprednisolone for 3 days, followed by oral predniso

135 ne sodium succinate equivalent to 1000 mg of methylprednisolone for 5 days, 0.4 mg/kg/d of intravenou

136 ostratum conidia preexposed to 0.32 mg/mL of methylprednisolone for 7 days in immunocompetent flies l

137 a short course of corticosteroids (1 mg/d of methylprednisolone for about 2 weeks).

138 ients in TAC/MMF and 20% in TAC/SRL received methylprednisolone for acute rejection/SCAR.

139 ch, we evaluated the efficacy of intravenous methylprednisolone for HCPS treatment, through a paralle

140 Our results do not support the use of methylprednisolone for HCPS.

141 Patients were treated with alemtuzumab and methylprednisolone for induction, followed by tacrolimus

142 d a history of epidural spinal injections of methylprednisolone for low back pain.

143 Subjects received concurrent 2 mg/kg per day methylprednisolone for more than or equal to 10 days.

144 RS trial does not support the routine use of methylprednisolone for patients undergoing cardiopulmona

145 se results do not support the routine use of methylprednisolone for persistent ARDS despite the impro

146 he efficacy of a single preoperative dose of methylprednisolone for preventing postoperative complica

147 or paraspinal glucocorticoid injection with methylprednisolone from a single compounding pharmacy.

148 as admitted to the hospital and treated with methylprednisolone, furosemide, and C1 esterase inhibito

149 None responded to methylprednisolone, given for a minimum of 3 days.

150 idence of postoperative complications in the methylprednisolone group (31.2% vs. 47.3%; p = 0.042).

151 ss treatment failure among patients from the methylprednisolone group (8 patients [13%]) compared wit

152 on) and from 16.4 (12.5) to 1.6 (3.4) in the methylprednisolone group (90% reduction; mean difference

153 0.3 to 38.6 percent) and 29.2 percent in the methylprednisolone group (95 percent confidence interval

154 A total of 27 (33%) subjects in the methylprednisolone group and 40 (42%) in the placebo gro

155 of 67 and 32 of 67 (48%) in the intravenous methylprednisolone group and 51 (73%) of 70 and 35 of (5

156 lycemia occurred in 11 patients (18%) in the methylprednisolone group and in 7 patients (12%) in the

157 etween the 2 groups (6 patients [10%] in the methylprednisolone group vs 9 patients [15%] in the plac

158 atients in the gentamicin group vs 15 in the methylprednisolone group).

159 tient in the gentamicin group and two in the methylprednisolone group.

160 ree in the gentamicin group and three in the methylprednisolone group.

161 surgery incorporated, both the 80- and 40-mg methylprednisolone groups had lower likelihood of surger

162 thylprednisolone, </=240 mg/d) or high-dose (methylprednisolone, >240 mg/d) groups based on CS dosage

163 ving placebo, patients receiving intravenous methylprednisolone had a somewhat shorter initial period

164 Patients treated with methylprednisolone had progressive and sustained reducti

165 Methylprednisolone has been applied to reduce inflammati

166 Injection of contaminated methylprednisolone has resulted in an unprecedented nati

167 nance tacrolimus, mycophenolate mofetil, and methylprednisolone immunosuppression.

168 ith Therapeutic Plasma Exchange (TPE) and IV methylprednisolone improved the condition of the patient

169 tudy was to determine whether intraoperative methylprednisolone improves post-operative recovery in n

170 Methylprednisolone in a dose of 1 mg x kg(-1) x day(-1)

171 dy was developed to evaluate alemtuzumab and methylprednisolone in combination.

172 mus and mycophenolate in all three arms, and methylprednisolone in groups A and C only (standard clin

173 ARDS Network currently is testing the use of methylprednisolone in late ARDS.

174 ficial effect of pulse high-dose intravenous methylprednisolone in patients with allergic bronchopulm

175 An early short course of methylprednisolone in patients with moderate to severe C

176 Topical tacrolimus was more effective than methylprednisolone in reducing the CFS score at week 10

177 on of IL-1 receptor antagonist anakinra plus methylprednisolone in severe COVID-19 pneumonia with hyp

178 exchange was more effective than intravenous methylprednisolone in the achievement of renal recovery

179 us (SLE) was the use of cyclophosphamide and methylprednisolone in the treatment of lupus nephritis.

180 Treatment with methylprednisolone increased disease severity in infecte

181 flow cytometry, and ELISA demonstrated that methylprednisolone increased the expression of miRNA-98

182 Methylprednisolone increased the number of ventilator-fr

183 adult rats with the antiinflammatory steroid methylprednisolone increases the activity of matrix meta

184 Early methylprednisolone infusion (n = 55) compared with place

185 cluded rituximab infusions, cyclophosphamide/methylprednisolone infusions, prednisone and mycophenola

186 ventions included mechanical ventilation and methylprednisolone infusions.

187 d thrombin-induced platelet aggregation, and methylprednisolone inhibited ADP-induced aggregation to

188 received 4 doses over 14 days of 40 mg/mL of methylprednisolone injected into the middle ear.

189 to those that led the patient to undergo the methylprednisolone injection.

190 chronic tension-type headaches per month vs methylprednisolone injections (SMD, -2.5; 95% CI, -3.5 t

191 Methylprednisolone injections are a non-ablative, effect

192 Methylprednisolone injections for CTS have significant b

193 ungal infections as a result of contaminated methylprednisolone injections.

194 early intervention (EI) with intraarticular methylprednisolone into all synovitic joints or to conse

195 Scheme of three iv. pulses of methylprednisolone intravenously and the continuation of

196 Patients were grouped into lower-dose (methylprednisolone, </=240 mg/d) or high-dose (methylpre

197 Each group received daclizumab induction and methylprednisolone maintenance.

198 , and tacrolimus, mycophenolate mofetil, and methylprednisolone maintenance.

199 , and tacrolimus, mycophenolate mofetil, and methylprednisolone maintenance.

200 Treatment with anakinra plus methylprednisolone may be a valid therapeutic option in

201 Patients received 30 mg/kg of methylprednisolone (MP) (n = 77) or placebo (n = 76) pre

202 Patients were randomly assigned to methylprednisolone (MP) 16 mg twice daily or placebo (PL

203 0 patients with AR received immediate pulsed methylprednisolone (MP) and one untreated patient develo

204 The use of methylprednisolone (MP) and other corticosteroids for th

205 loped an animal model that demonstrates that methylprednisolone (MP) can block PV IgG-induced acantho

206 Glucocorticoids such as methylprednisolone (MP) have been used as analgesic and

207 closporine-A (CsA) and the anti-inflammatory methylprednisolone (MP) in a stroke model.

208 ls from healthy donors were exposed to 1 muM methylprednisolone (MP) in vitro and then subjected to m

209 Although methylprednisolone (MP) is currently the standard therap

210 Methylprednisolone (MP) is used to treat a variety of ne

211 ) promote recovery in animal models, whereas methylprednisolone (MP) promotes neurological recovery i

212 rt 1, matched unrelated donor transplant and methylprednisolone (MP) T-cell depletion (TCD) of donor

213 d to compare preoperative and intraoperative methylprednisolone (MP) to intraoperative MP alone with

214 tions following spinal cord injury (SCI) and methylprednisolone (MP) treatment of SCI.

215 Methylprednisolone (MP), a synthetic glucocorticoid agon

216 Cyclosporin A (CSA), methylprednisolone (MP), methotrexate (MTX), and mycophe

217 outcome) in patients treated with placebo or methylprednisolone (MP).

218 was superior to a 5-fold higher dose of free methylprednisolone (MP).

219 ized controlled trial of tri-iodothyronine+/-methylprednisolone [MP] therapy) undergoing PAC-guided a

220 following treatment with the corticosteroid methylprednisolone (MPL).

221 Methylprednisolone (mPSL) was applied to 31 (47.69%) pat

222 travenous bolus of 0.5 mg/kg per 12 hours of methylprednisolone (n = 61) or placebo (n = 59) for 5 da

223 exchanges (n = 70) or 3000 mg of intravenous methylprednisolone (n = 67).

224 e for all 7507 patients randomly assigned to methylprednisolone (n=3755) and to placebo (n=3752).

225 Of the 190 subjects enrolled, 176 (n = 81 methylprednisolone, n = 95 placebo) were included in thi

226 Proadrenomedullin levels were decreased with methylprednisolone on day 3 in patients with infectious

227 Protein C levels were increased with methylprednisolone on days 3 and 7 in patients with infe

228 Evaluate the effects of methylprednisolone on markers of inflammation, coagulati

229 fect of donor treatment with simvastatin and methylprednisolone on microvascular dysfunction and immu

230 tigate the effect of high-dose anakinra plus methylprednisolone on survival.

231 All patients received 80 mg of intravenous methylprednisolone on the first day.

232 In CRSwNP patients, treatment with methylprednisolone or anti-IL-5 resulted in the reductio

233 ived either intensive enteral nutrition plus methylprednisolone or conventional nutrition plus methyl

234 ent of EDE with the anti-inflammatory agents methylprednisolone or doxycycline preserves apical corne

235 Treatment of EDE with methylprednisolone or doxycycline reduced corneal permea

236 s were given aggressive therapy (intravenous methylprednisolone or oral prednisone 5-30 mg/kg/day; n

237 least seven days' duration to receive either methylprednisolone or placebo in a double-blind fashion.

238 n included studies were high (mostly > 40 mg methylprednisolone [or equivalent] per day).

239 The DA rats received simvastatin, methylprednisolone, or both 2 hr before heart donation.

240 Mice were treated daily with dexamethasone, methylprednisolone, or PBS from days 0 to 14 or days 10

241 ceived 80 mg of methylprednisolone, 40 mg of methylprednisolone, or placebo.

242 s treated with pulse cyclophosphamide, pulse methylprednisolone, or the combination of both.

243 Results With prednisolone, methylprednisolone, or triamcinolone, blood flow was rap

244 pical treatment with 5% IL-1Ra (P < .01), 1% methylprednisolone (P < .01), and 0.05% cyclosporin A (P

245 0.04), and to have been treated with pulsed methylprednisolone (P = 0.03).

246 y inhibited by 74% and 90% after exposure to methylprednisolone (P<0.05), 11% and 24% after exposure

247 antly in both groups (tacrolimus, P = 0.003; methylprednisolone, P = 0.008), whereas HLA-DR expressio

248 atment with high-dose pulse intravenous (IV) methylprednisolone permits a shorter course of therapy.

249 As compared with intravenous methylprednisolone, plasma exchange was associated with

250 tions supported by phase II clinical trials (methylprednisolone plus alemtuzumab or ibrutinib) seem b

251 ylprednisolone premedication, or intravenous methylprednisolone premedication plus oral prednisone fo

252 either placebo glucocorticoids, intravenous methylprednisolone premedication, or intravenous methylp

253 ular RhoA GTPase pathway activation, whereas methylprednisolone prevented activation of innate immune

254 reatment in combination with simvastatin and methylprednisolone prevents IRI and has beneficial effec

255 ngal meningitis associated with contaminated methylprednisolone produced by a compounding pharmacy ha

256 more aggressive approaches such as high-dose methylprednisolone pulse therapy are used to provide tra

257 lative glucocorticoid doses (daily dose plus methylprednisolone pulse) during the first 6 months both

258 ections (cRR, 0.05 [0.02-0.6]; P = 0.01) and methylprednisolone pulses negatively affected the outcom

259 ympanic administration of the corticosteroid methylprednisolone reduces vertigo compared with gentami

260 were desmopressin use, triiodothyronine and methylprednisolone replacement, fluid management, vasopr

261 steroid injections (ESIs) with contaminated methylprednisolone resulted in an outbreak of fungal men

262 cute rejections: the fourth was treated with methylprednisolone, rituximab, and immunoglobulin.

263 CI, 1.44-7.59; P<0.001), and treatment with methylprednisolone (RR, 2.31; 95% CI, 1.07-4.94; P=0.03)

264 alone or in combination with simvastatin and methylprednisolone significantly reduced cardiac troponi

265 A single preoperative dose of methylprednisolone significantly reduces the length of h

266 With initial methylprednisolone sodium succinate and alternate treatm

267 ppressive therapy, consisting of intravenous methylprednisolone sodium succinate equivalent to 1000 m

268 She was treated with methylprednisolone sodium succinate, plasma exchange, an

269 Previous studies showed that methylprednisolone specifically increased Na(+)/H(+) exc

270 lly administration of levothyroxine (T4) and methylprednisolone (steroid, i.e., the "T4 Protocol") in

271 ssion was achieved with cyclophosphamide and methylprednisolone systemic therapy.

272 sion treatment with antithymyocyte globulin, methylprednisolone, tacrolimus, mycophenolate mofetil, a

273 ved 80 mg of methylprednisolone and 40 mg of methylprednisolone than in those who received placebo (d

274 Despite infusions of methylprednisolone, the patient expired on hospital day

275 In addition, starting methylprednisolone therapy more than two weeks after the

276 Methylprednisolone therapy was associated with greater i

277 elevated but not differentially affected by methylprednisolone therapy.

278 and laboratory investigation and a trial of methylprednisolone therapy.

279 nt (placebo, oral prednisone, or intravenous methylprednisolone), time, and treatment x time interact

280 The addition of methylprednisolone to antibody therapy correlated with i

281 ition of a single pulsed dose of intravenous methylprednisolone to conventional intravenous immune gl

282 etermine whether the addition of intravenous methylprednisolone to conventional primary therapy for K

283 Two non-responders switched from methylprednisolone to gentamicin.

284 e hypothesis of inferiority of intratympanic methylprednisolone to oral prednisone for primary treatm

285 of 30 placebo-treated patients and 11 of 30 methylprednisolone-treated patients progressed to the pr

286 Corneas of immunocompetent, methylprednisolone-treated, and cyclophosphamide-treated

287 renomedullin levels were lower by day 3 with methylprednisolone treatment (p = .004).

288 id, and the particulate steroids cortivazol, methylprednisolone, triamcinolone, and prednisolone.

289 .21, 0, and 0 capillaries per millimeter for methylprednisolone, triamcinolone, or prednisolone, resp

290 receive a single preoperative 500 mg dose of methylprednisolone versus placebo.

291 iratory distress syndrome, administration of methylprednisolone was associated with improvement in im

292 h anti-CD154 mAb, mycophenolate mofetil, and methylprednisolone was associated with persistently low

293 Methylprednisolone was associated with reductions in vas

294 Methylprednisolone was associated with significantly inc

295 In this analysis, methylprednisolone was protective at 1 center, with an O

296 eceived placebo, those who received 80 mg of methylprednisolone were less likely to have surgery (odd

297 The number of emergency visit and doses of methylprednisolone were significantly reduced compared t

298 Administration of methylprednisolone, which has become common practice in

299 e patient responded to high-dose intravenous methylprednisolone, which resulted in improvement of ren

300 -1.47), and two large trials of intravenous methylprednisolone with altogether 467 participants, in